These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 30470902)
1. Amyotrophic lateral sclerosis associated with statins. A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase). Macías Saint-Gerons D; Castro JL Eur J Clin Pharmacol; 2019 Apr; 75(4):587-589. PubMed ID: 30470902 [No Abstract] [Full Text] [Related]
2. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Edwards IR; Star K; Kiuru A Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877 [TBL] [Abstract][Full Text] [Related]
3. Cataracts and statins. A disproportionality analysis using data from VigiBase. Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197 [TBL] [Abstract][Full Text] [Related]
4. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. Gaimari A; Fusaroli M; Raschi E; Baldin E; Vignatelli L; Nonino F; De Ponti F; Mandrioli J; Poluzzi E Drug Saf; 2022 Jun; 45(6):663-673. PubMed ID: 35610460 [TBL] [Abstract][Full Text] [Related]
5. Statins and amyotrophic lateral sclerosis--the level of evidence for an association. Sørensen HT; Lash TL J Intern Med; 2009 Dec; 266(6):520-6. PubMed ID: 19930099 [TBL] [Abstract][Full Text] [Related]
6. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724 [TBL] [Abstract][Full Text] [Related]
7. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. Golomb BA; Verden A; Messner AK; Koslik HJ; Hoffman KB Drug Saf; 2018 Apr; 41(4):403-413. PubMed ID: 29427042 [TBL] [Abstract][Full Text] [Related]
8. Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database. Gras-Champel V; Batteux B; Masmoudi K; Liabeuf S Muscle Nerve; 2019 Oct; 60(4):382-386. PubMed ID: 31298743 [TBL] [Abstract][Full Text] [Related]
9. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Strandell J; Bate A; Hägg S; Edwards IR Br J Clin Pharmacol; 2009 Sep; 68(3):427-34. PubMed ID: 19740401 [TBL] [Abstract][Full Text] [Related]
10. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase Montastruc F; Benevent J; Rousseau V; Durrieu G; Sommet A; Montastruc JL Fundam Clin Pharmacol; 2019 Feb; 33(1):108-112. PubMed ID: 30098074 [TBL] [Abstract][Full Text] [Related]
11. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Sørensen HT; Riis AH; Lash TL; Pedersen L Circ Cardiovasc Qual Outcomes; 2010 Jul; 3(4):413-7. PubMed ID: 20530788 [TBL] [Abstract][Full Text] [Related]
12. Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. van Hunsel F; van Puijenbroek E; de Jong-van den Berg L; van Grootheest K Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):26-32. PubMed ID: 19953500 [TBL] [Abstract][Full Text] [Related]
13. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Fraunfelder FW; Richards AB Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555 [TBL] [Abstract][Full Text] [Related]
14. Statins, regulatory T cells and amyotrophic lateral sclerosis. Goldstein MR; Mascitelli L; Pezzetta F Drug Saf; 2008; 31(2):181; author reply 181-3. PubMed ID: 18217793 [No Abstract] [Full Text] [Related]
15. [Statins--the pattern of adverse effects with empahsis on mental reactions. Data from a national and an international database]. Buajordet I; Madsen S; Olsen H Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3210-3. PubMed ID: 9411859 [TBL] [Abstract][Full Text] [Related]
16. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726 [TBL] [Abstract][Full Text] [Related]
17. Establishing the correlation between statins and cough: case series report and analysis of adverse drug reactions in the international databases. Carnovale C; Pellegrino P; Perrone V; Gentili M; Brusadelli T; Antoniazzi S; Speziali A; Borsadoli C; Pozzi M; Clementi E; Radice S Eur J Clin Pharmacol; 2014 Dec; 70(12):1529-31. PubMed ID: 25245842 [No Abstract] [Full Text] [Related]
18. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924 [TBL] [Abstract][Full Text] [Related]
19. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055 [TBL] [Abstract][Full Text] [Related]
20. Novel statistical tools for monitoring the safety of marketed drugs. Almenoff JS; Pattishall EN; Gibbs TG; DuMouchel W; Evans SJ; Yuen N Clin Pharmacol Ther; 2007 Aug; 82(2):157-66. PubMed ID: 17538548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]